Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SNS-032 · 2 trials · 5 indications
| Arm | Type | Description |
|---|---|---|
| Dose-escalation of SNS-032 injection | EXPERIMENTAL | Patients escalated to MTD starting in Cohort 1 of 15 mg/m2 of SNS-032 injection, with 1.5-fold increase each cohort and a maximum loading dose increase of 10 mg/m2. Each dose cohort will have a minimum of 3 patients each with advanced CLL or MM. Dose escalation continues in the absence of Cycle 1 DLT criteria until an MTD is achieved for each disease type to a maximum of 7 cohorts at a high dose of 70 mg/m2. Stage 2 tests at MTD in larger group. |
| Name | Type | Description |
|---|---|---|
| SNS-032 Injection | DRUG | Stage 1: Escalating doses of SNS-032 on days 1, 8 and 15 per 28 day cycle Stage 2: Same as stage 1 except SNS-032 administered at the maximum tolerated dose established in stage 1 |
Inclusion Criteria: * Cytologically or histologically confirmed chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), or multiple myeloma (MM). * Evidence of relapsed disease * Measurable disease * Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1 Exclusion Cri...
SNS-032 is an investigational small molecule being studied for the treatment of B-lymphoid malignancies and tumors. It has been evaluated in Phase 1 clinical trials for advanced solid tumors and advanced B-lymphoid malignancies, including chronic lymphocytic leukemia, mantle cell lymphoma, and multiple myeloma.
SNS-032 is being developed by Viracta Therapeutics, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol VIRX. The company has conducted clinical trials of SNS-032 in the United States.
SNS-032 is in Phase 1 clinical development. It is an investigational drug that has completed two Phase 1 trials, one in advanced solid tumors and one in advanced B-lymphoid malignancies. It is not FDA approved and remains in clinical development.
SNS-032 has been studied in two completed Phase 1 clinical trials: NCT00292864, which assessed one-hour infusions of SNS-032 in 25 patients with advanced solid tumors, and NCT00446342, which studied intravenously administered SNS-032 in 21 patients with advanced B-lymphoid malignancies.
SNS-032 is a small molecule that targets cyclin-dependent kinases, which are enzymes involved in cell cycle regulation. By inhibiting these kinases, SNS-032 is designed to interfere with cancer cell proliferation. This mechanism is being investigated for its potential in treating certain cancers.